1 week Ago By Defense World Staff
Corvus Pharmaceuticals, Inc. ( NASDAQ:CRVS – Get Free Report ) has been given an average rating of “Buy” by the five analysts that are presently covering the company, MarketBeat reports. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company.
The average 12 month target price among brokerages that have covered the stock in the last year is $12.38. A number of analysts have commented on CRVS shares.
Oppenheimer upped their price target on Corvus Pharmaceuticals from $8.00 to $14.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th.
LADENBURG THALM/SH SH raised their price target on Corvus Pharmaceuticals from $12.00 to $21.00 and gave the stock a “buy” rating in a research report on Monday, September 16th.
HC Wainwright started coverage on shares of Corvus Pharmaceuticals in a report on Thursday. They issued a “buy” rating and a $11.00 price target on the stock.
StockNews.com downgraded shares of Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, October 31st. Finally, Mizuho upgraded Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 22nd.
Read Our Latest Report on Corvus Pharmaceuticals Institutional Investors Weigh In On Corvus Pharmaceuticals Corvus Pharmaceuticals Stock Performance CRVS stock opened at $5.83 on Thursday. Corvus Pharmaceuticals has a 52-week low of $1.
30 and a 52-week high of $10.00. The firm has a market capitalization of $374.
62 million, a price-to-earnings ratio of -6.27 and a beta of 1.07.
The firm has a 50 day moving average price of $7.67 and a 200-day moving average price of $5.29.
Corvus Pharmaceuticals Company Profile ( Get Free Report Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. Further Reading Five stocks we like better than Corvus Pharmaceuticals Top Biotech Stocks: Exploring Innovation Opportunities Quantum Opportunity: Skywater Technology’s Long-Term Potential Where to Find Earnings Call Transcripts Nebius Group: The Rising Star in AI Infrastructure Top Stocks Investing in 5G Technology MarketBeat Week in Review – 12/30 – 1/03 Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.
com's FREE daily email newsletter ..
